{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:49:03Z","timestamp":1789051743156,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T00:00:00Z","timestamp":1531872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s10067-018-4202-3","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T05:52:55Z","timestamp":1531979575000},"page":"2939-2945","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Serum-soluble folate receptor \u03b2 as a biomarker for the activity of rheumatoid arthritis synovitis and the response to anti-TNF agents"],"prefix":"10.1007","volume":"37","author":[{"given":"Hideo","family":"Otsubo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Tsuneyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takemasa","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setsuro","family":"Komiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takami","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,18]]},"reference":[{"key":"4202_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1146\/annurev-nutr-072610-145133","volume":"31","author":"R Zhao","year":"2011","unstructured":"Zhao R, Diop-Bove N, Visentin M, Goldman ID (2011) Mechanisms of membrane transport of folates into cells and across epithelia. Annu Rev Nutr 31:177\u2013201","journal-title":"Annu Rev Nutr"},{"key":"4202_CR2","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.4161\/cbt.22020","volume":"13","author":"SK Desmoulin","year":"2012","unstructured":"Desmoulin SK, Hou Z, Gangjee A, Matherly LH (2012) The human proton-coupled folate transporter: biology and therapeutic applications to cancer. Cancer Biol Ther 13:1355\u20131373","journal-title":"Cancer Biol Ther"},{"key":"4202_CR3","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.addr.2004.01.001","volume":"56","author":"H Elnakat","year":"2004","unstructured":"Elnakat H, Ratnam M (2004) Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 56:1067\u20131084","journal-title":"Adv Drug Deliv Rev"},{"key":"4202_CR4","first-page":"3396","volume":"52","author":"SD Weitman","year":"1992","unstructured":"Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR Jr et al. (1992) Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res:52:3396\u2013401.","journal-title":"Cancer Res"},{"key":"4202_CR5","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1002\/1529-0131(199908)42:8<1609::AID-ANR7>3.0.CO;2-L","volume":"42","author":"N Nakashima-Matsushita","year":"1999","unstructured":"Nakashima-Matsushita N, Homma T, Yu S, Matsuda T, Sunahara N, Nakamura T, Tsukano M, Ratnam M, Matsuyama T (1999) Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum 42:1609\u20131616","journal-title":"Arthritis Rheum"},{"key":"4202_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3109\/03009742.2011.605391","volume":"41","author":"Y Tsuneyoshi","year":"2012","unstructured":"Tsuneyoshi Y, Tanaka M, Nagai T, Sunahara N, Matsuda T, Sonoda T, Ijiri K, Komiya S, Matsuyama T (2012) Functional folate receptor beta-expressing macrophages in osteoarthritis synovium and their M1\/M2 expression profiles. Scand J Rheumatol 41:132\u2013140","journal-title":"Scand J Rheumatol"},{"key":"4202_CR7","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1093\/annonc\/mdv250","volume":"26","author":"JA Ledermann","year":"2015","unstructured":"Ledermann JA, Canevari S, Thigpen T (2015) Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann Oncol 26:2034\u20132043","journal-title":"Ann Oncol"},{"key":"4202_CR8","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/1758834015584763","volume":"7","author":"I Vergote","year":"2015","unstructured":"Vergote I, Leamon CP (2015) Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors. Ther Adv Med Oncol 7:206\u2013218","journal-title":"Ther Adv Med Oncol"},{"key":"4202_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/978-94-007-2199-9_9","volume":"56","author":"J Yang","year":"2012","unstructured":"Yang J, Vlashi E, Low P (2012) Folate-linked drugs for the treatment of cancer and inflammatory diseases. Subcell Biochem 56:163\u2013179","journal-title":"Subcell Biochem"},{"key":"4202_CR10","first-page":"253","volume":"27","author":"EL Matteson","year":"2009","unstructured":"Matteson EL, Lowe VJ, Prendergast FG, Crowson CS, Moder KG, Morgenstern DE et al (2009) Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan. Clin Exp Rheumatol 27:253\u2013259","journal-title":"Clin Exp Rheumatol"},{"key":"4202_CR11","doi-asserted-by":"publisher","first-page":"R106","DOI":"10.1186\/ar3831","volume":"14","author":"T Nagai","year":"2012","unstructured":"Nagai T, Kyo A, Hasui K, Takao S, Matsuyama T (2012) Efficacy of an immunotoxin to folate receptor beta in the intra-articular treatment of antigen-induced arthritis. Arthritis Res Ther 14:R106","journal-title":"Arthritis Res Ther"},{"key":"4202_CR12","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1002\/art.22082","volume":"54","author":"T Nagai","year":"2006","unstructured":"Nagai T, Tanaka M, Tsuneyoshi Y, Matsushita K, Sunahara N, Matsuda T, Yoshida H, Komiya S, Onda M, Matsuyama T (2006) In vitro and in vivo efficacy of a recombinant immunotoxin against folate receptor beta on the activation and proliferation of rheumatoid arthritis synovial cells. Arthritis Rheum 54:3126\u20133134","journal-title":"Arthritis Rheum"},{"key":"4202_CR13","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1002\/art.21228","volume":"52","author":"R Nagayoshi","year":"2005","unstructured":"Nagayoshi R, Nagai T, Matsushita K, Sato K, Sunahara N, Matsuda T, Nakamura T, Komiya S, Onda M, Matsuyama T (2005) Effectiveness of anti-folate receptor beta antibody conjugated with truncated Pseudomonas exotoxin in the targeting of rheumatoid arthritis synovial macrophages. Arthritis Rheum 52:2666\u20132675","journal-title":"Arthritis Rheum"},{"key":"4202_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s11307-015-0876-y","volume":"18","author":"LE Kelderhouse","year":"2016","unstructured":"Kelderhouse LE, Mahalingam S, Low PS (2016) Predicting response to therapy for autoimmune and inflammatory diseases using a folate receptor-targeted near-infrared fluorescent imaging agent. Mol Imaging Biol 18:201\u2013208","journal-title":"Mol Imaging Biol"},{"key":"4202_CR15","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1021\/acs.molpharmaceut.5b00134","volume":"12","author":"LE Kelderhouse","year":"2015","unstructured":"Kelderhouse LE, Robins MT, Rosenbalm KE, Hoylman EK, Mahalingam S, Low PS (2015) Prediction of response to therapy for autoimmune\/inflammatory diseases using an activated macrophage-targeted radioimaging agent. Mol Pharm 12:3547\u20133555","journal-title":"Mol Pharm"},{"key":"4202_CR16","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1096\/fj.00-0415hyp","volume":"15","author":"P B\u00fctikofer","year":"2001","unstructured":"B\u00fctikofer P, Malherbe T, Boschung M, Roditi I (2001) GPI-anchored proteins: now you see \u2018em, now you don\u2019t. FASEB J 15:545\u2013548","journal-title":"FASEB J"},{"key":"4202_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4137\/BMI.S15245","volume":"9","author":"EB Somers","year":"2014","unstructured":"Somers EB, O\u2019Shannessy DJ (2014) Folate receptor alpha, mesothelin and megakaryocyte potentiating factor as potential serum markers of chronic kidney disease. Biomark Insights 9:29\u201337","journal-title":"Biomark Insights"},{"key":"4202_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1757-2215-6-29","volume":"6","author":"DJ O'Shannessy","year":"2013","unstructured":"O'Shannessy DJ, Somers EB, Palmer LM, Thiel RP, Oberoi P, Heath R et al (2013) Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4. J Ovarian Res 6:29","journal-title":"J Ovarian Res"},{"key":"4202_CR19","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","volume":"73","author":"JL Nam","year":"2014","unstructured":"Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, Gossec L, Landewe R, Smolen JS, Buch MH (2014) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 73:516\u2013528","journal-title":"Ann Rheum Dis"},{"key":"4202_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.autrev.2012.10.020","volume":"12","author":"F Atzeni","year":"2013","unstructured":"Atzeni F, Benucci M, Sall\u00ec S, Bongiovanni S, Boccassini L, Sarzi-Puttini P (2013) Different effects of biological drugs in rheumatoid arthritis. Auoimmune Rev 12:575\u2013579","journal-title":"Auoimmune Rev"},{"key":"4202_CR21","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1136\/ard.2004.029751","volume":"64","author":"JJ Haringman","year":"2005","unstructured":"Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D et al (2005) Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64:834\u2013838","journal-title":"Ann Rheum Dis"},{"key":"4202_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/art.20764","volume":"52","author":"AI Catrina","year":"2005","unstructured":"Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, Klareskog L, Ulfgren AK (2005) Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 52:61\u201372","journal-title":"Arthritis Rheum"},{"key":"4202_CR23","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1002\/art.11098","volume":"48","author":"TJ Smeets","year":"2003","unstructured":"Smeets TJ, Kraan MC, van Loon ME, Tak PP (2003) Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 48:2155\u20132162","journal-title":"Arthritis Rheum"},{"key":"4202_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"key":"4202_CR25","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/art.1780290816","volume":"29","author":"R Altman","year":"1986","unstructured":"Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K et al (1986) Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 29:1039\u20131049","journal-title":"Arthritis Rheum"},{"key":"4202_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/ard.2006.054205","volume":"66","author":"E Inoue","year":"2007","unstructured":"Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N (2007) Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis 66:407\u2013409","journal-title":"Ann Rheum Dis"},{"key":"4202_CR27","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K","volume":"41","author":"AM Gestel van","year":"1998","unstructured":"van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41:1845\u20131850","journal-title":"Arthritis Rheum"},{"key":"4202_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1089\/mab.2014.0072","volume":"34","author":"T Nagai","year":"2015","unstructured":"Nagai T, Furusho Y, Li H, Hasui K, Matsukita S, Sueyoshi K, Yanagi M, Hatae M, Takao S, Matsuyama T (2015) Production of a high-affinity monoclonal antibody reactive with folate receptors alpha and beta. Monoclon Antib Immunodiagn Immunother 34:181\u2013190","journal-title":"Monoclon Antib Immunodiagn Immunother"},{"key":"4202_CR29","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.joca.2016.04.010","volume":"24","author":"VB Kraus","year":"2016","unstructured":"Kraus VB, McDaniel G, Huebner JL, Stabler TV, Pieper CF, Shipes SW, Petry NA, Low PS, Shen J, McNearney TA, Mitchell P (2016) Direct in vivo evidence of activated macrophages in human osteoarthritis. Osteoarthr Cartil 24:1613\u20131621","journal-title":"Osteoarthr Cartil"},{"key":"4202_CR30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2013-203923","volume":"74","author":"IY Choi","year":"2015","unstructured":"Choi IY, Gerlag DM, Herenius MJ, Thurlings RM, Wijbrandts CA, Foell D, Vogl T, Roth J, Tak PP, Holzinger D (2015) MRP8\/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. MRP8\/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis 74:499\u2013505","journal-title":"Ann Rheum Dis"},{"key":"4202_CR31","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.4049\/jimmunol.145.12.4154","volume":"145","author":"KL MacNaul","year":"1990","unstructured":"MacNaul KL, Hutchinson NI, Parsons JN, Bayne EK, Tocci MJ (1990) Analysis of IL-1 and TNF-alpha gene expression in human rheumatoid synoviocytes and normal monocytes by in situ hybridization. J Immunol 145:4154\u20134166","journal-title":"J Immunol"},{"key":"4202_CR32","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1136\/ard.2011.153023","volume":"70","author":"T Takeuchi","year":"2011","unstructured":"Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, Koike T (2011) Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis 70:1208\u20131215","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4202-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4202-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4202-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T20:52:26Z","timestamp":1693774346000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4202-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,18]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["4202"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4202-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,18]]},"assertion":[{"value":"11 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Human Investigation Committee of Kagoshima University, and we obtained written informed consent from all patients before initiation of the study, according to the Declaration of Helsinki (October 2008).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}